Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dave Singh

Showing results (441-450 of 505) with videos related to

Pageof 51
Sort By:
American Journal of Respiratory and Critical Care Medicine|December 17, 2020
Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal AnalysisZhang Wang, Nicholas Locantore, Koirobi Haldar, et al.
Annals of the American Thoracic Society|October 27, 2020
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACTMark T Dransfield, Courtney Crim, Gerard J Criner, et al.
Respiratory Research|May 29, 2024
Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPDPhillip D Monk, Jody L Brookes, Victoria J Tear, et al.
Respiratory Medicine|December 5, 2022
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysisSamuel Bardsley, Gerard J Criner, David M G Halpin, et al.
American Journal of Respiratory and Critical Care Medicine|May 31, 2017
Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease MacrophagesMartin A Bewley, Julie A Preston, Mohammed Mohasin, et al.
Clinical Pharmacology and Therapeutics|December 20, 2023
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary DiseaseFred Reid, Dave Singh, Muna Albayaty, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|November 18, 2021
Discordant diagnostic criteria for pneumonia in COPD trials: a reviewRobert A Wise, Mona Bafadhel, Courtney Crim, et al.
European Journal of Preventive Cardiology|March 4, 2025
Identification and management of cardiopulmonary risk in patients with COPD: a multidisciplinary consensus and modified Delphi studyChris P Gale, John R Hurst, Nathaniel M Hawkins, et al.
Respiratory Research|December 8, 2023
An epithelial gene signature of trans-IL-6 signaling defines a subgroup of type 2-low asthmaZaid W El-Husseini, Dmitry Khalenkow, Andy Lan, et al.
The New England Journal of Medicine|May 20, 2024
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 InflammationSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Pageof 51

Showing results (441-450 of 505) with videos related to

Sort By:
Pageof 51
American Journal of Respiratory and Critical Care Medicine|December 17, 2020
Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal AnalysisZhang Wang, Nicholas Locantore, Koirobi Haldar, et al.
Annals of the American Thoracic Society|October 27, 2020
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACTMark T Dransfield, Courtney Crim, Gerard J Criner, et al.
Respiratory Research|May 29, 2024
Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPDPhillip D Monk, Jody L Brookes, Victoria J Tear, et al.
Respiratory Medicine|December 5, 2022
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysisSamuel Bardsley, Gerard J Criner, David M G Halpin, et al.
American Journal of Respiratory and Critical Care Medicine|May 31, 2017
Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease MacrophagesMartin A Bewley, Julie A Preston, Mohammed Mohasin, et al.
Clinical Pharmacology and Therapeutics|December 20, 2023
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary DiseaseFred Reid, Dave Singh, Muna Albayaty, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|November 18, 2021
Discordant diagnostic criteria for pneumonia in COPD trials: a reviewRobert A Wise, Mona Bafadhel, Courtney Crim, et al.
European Journal of Preventive Cardiology|March 4, 2025
Identification and management of cardiopulmonary risk in patients with COPD: a multidisciplinary consensus and modified Delphi studyChris P Gale, John R Hurst, Nathaniel M Hawkins, et al.
Respiratory Research|December 8, 2023
An epithelial gene signature of trans-IL-6 signaling defines a subgroup of type 2-low asthmaZaid W El-Husseini, Dmitry Khalenkow, Andy Lan, et al.
The New England Journal of Medicine|May 20, 2024
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 InflammationSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Pageof 51